HRS4R
Vull donar

JAVIER ABEL MENÉNDEZ MENÉNDEZ

Firma
JAVIER ABEL MENÉNDEZ-MENÉNDEZ
Posició
Cap de Grup - R4
Caps de Grup - R4

Projectes

Codi oficial: PID2019-104055GB-I00 Data inici: 01/06/2020 Data fi: 31/05/2023 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO / Ajuda: 242,000 €
Codi oficial: CP20/00003 Data inici: 01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €

Publicacions

Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin a 6 ß 1 drives endocrine resistance in breast cancer cells.

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882

Tramonti A, Cuyàs E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusà A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzolà F, Menendez JA

Metformin Is a Pyridoxal-5'-phosphate (PLP)-Competitive Inhibitor of SHMT2.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164009

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168

Verdura S, Cuyàs E, Ruiz-Torres V, Micol V, Joven J, Bosch-Barrera J, Menendez JA

Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Pharmaceuticals, 2021, 14 dx.doi.org/10.3390/ph14060559

Menendez JA, Papadimitropoulou A, Vander Steen T, Cuyàs E, Oza-Gajera BP, Verdura S, Espinoza I, Vellon L, Mehmi I, Lupu R

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13051132

Castañé H, Baiges-Gaya G, Hernández-Aguilera A, Rodríguez-Tomàs E, Fernández-Arroyo S, Herrero P, Delpino-Rius A, Canela N, Menendez JA, Camps J, Joven J

Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview.

Biomolecules, 2021, 11 dx.doi.org/10.3390/biom11030473

Schroeder B, Vander Steen T, Espinoza I, Venkatapoorna CMK, Hu Z, Silva FM, Regan K, Cuyàs E, Meng XW, Verdura S, Arbusà A, Schneider PA, Flatten KS, Kemble G, Montero J, Kaufmann SH, Menendez JA, Lupu R

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells.

CELL DEATH & DISEASE, 2021, 12, 977-977 dx.doi.org/10.1038/s41419-021-04262-x

Cuyàs E, Verdura S, Martin-Castillo B, Menendez JA

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology.

Frontiers in oncology, 2021, 10, 620641-620641 dx.doi.org/10.3389/fonc.2020.620641

Golden E, Rashwan R, Woodward EA, Sgro A, Wang E, Sorolla A, Waryah C, Tie WJ, Cuyàs E, Ratajska M, Kardas I, Kozlowski P, Johnstone EKM, See HB, Duffy C, Parry J, Lagerborg KA, Czapiewski P, Menendez JA, Gorczynski A, Wasag B, Pfleger KDG, Curtis C, Lee BK, Kim J, Cursons J, Pavlos NJ, Biernat W, Jain M, Woo AJ, Redfern A, Blancafort P

The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.

NATURE COMMUNICATIONS, 2021, 12, 1920-1920 dx.doi.org/10.1038/s41467-021-22101-7

Alarcón T, Sardanyés J, Guillamon A, Menendez JA

Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs.

PLoS Computational Biology, 2021, 17 dx.doi.org/10.1371/journal.pcbi.1008408

Formulari de contacte

Coneix l’IDIBGI!

menu